TPST — Tempest Therapeutics, Inc.
$0.5110-2.16%
Last close: · regular session
After-hours $0.5183 +1.43% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for TPST in the TickerWise workspace.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 24
- Website: https://www.tempesttx.com
Latest SEC filings for TPST
Latest TPST news
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.